Anika Therapeutics Inc. Working Capital

Working Capital of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending September 29, 2021 was $137 Million (a 0.45% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -2.5%
  • Annual Working Capital for 2020 was $141 Million (a -35.55% decrease from previous year)
  • Annual Working Capital for 2019 was $218 Million (a 13.76% increase from previous year)
  • Annual Working Capital for 2018 was $192 Million (a -0.83% decrease from previous year)
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Anika Therapeutics Inc.

Most recent Working Capitalof ANIK including historical data for past 10 years.

Interactive Chart of Working Capital of Anika Therapeutics Inc.

Anika Therapeutics Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $137.01 $136.39 $126.5
2020 $140.52 $170.74 $193.38 $134.94 $140.52
2019 $218.03 $212.62 $179.54 $198.09 $218.03
2018 $191.65 $186.29 $178.46 $194.07 $191.65
2017 $193.25 $187.33 $179.44 $166.83 $193.25
2016 $161.64 $153.49 $144.12 $137.04 $161.64
2015 $159.16 $155.04 $147.77 $139.76 $159.16
2014 $131.86 $122.22 $112.2 $105.77 $131.86
2013 $85.31 $84.65 $74.77 $67.95 $85.31
2012 $62.93 $56.25 $54.38 $51.07 $62.93
2011 $49.6 $43.51 $40.1 $37.0 $49.6
2010 $36.95 $36.95

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.